{"title":"巨细胞病毒和其他人类疱疹病毒输血相关感染。","authors":"Kühn","doi":"10.1159/000025258","DOIUrl":null,"url":null,"abstract":"<p><p>Of all human herpesviruses, human cytomegalovirus (HCMV) is the most significant cause of transfusion-associated (TA) morbidity and mortality. The problem of TA HCMV infection differs from that of other transfusion-transmitted infections in that only certain groups of patients require HCMV-free blood or blood components, i.e. seronegative pregnant women, premature infants of low birth weight who are born to seronegative mothers, seronegative recipients of allogeneic bone marrow transplants from seronegative donors, seronegative AIDS patients, and seronegative immunosuppressed patients in general. HCMV is strictly cell-associated, and transmission appears to be due to reactivation of latent virus in white blood cells. TA HCMV infec-tion in risk groups can be minimized by selection of HCMV-seronegative donors. Since transmission of HCMV from seropositive donors by blood components containing fewer than 10 7 leukocytes per unit is unlikely, leukodepletion of transfusion products by filtration is an effective alternative to the use of seronegative blood products. Other human herpesviruses causing TA infections are Epstein-Barr virus (EBV) and the human herpesviruses 6 and 7 (HHV-6, HHV-7), whereas transmissions of herpes simplex viruses (HSV-1, HSV-2) and varicella-zoster virus (VZV) by blood transfusion - if occurring at all - are extremely rare events. Frequency and clinical significance of TA infections with the human herpesvirus 8 (HHV-8) have not yet been fully elucidated. Despite the low seroprevalence of HHV-8 in Germany, its oncogenic potential merits attention, and strategies to prevent transmission and spread of HHV-8 by blood and blood products should be discussed. Copyright 2000 S. Karger GmbH, Freiburg</p>","PeriodicalId":13632,"journal":{"name":"Infusionstherapie und Transfusionsmedizin","volume":"27 3","pages":"138-143"},"PeriodicalIF":0.0000,"publicationDate":"2000-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000025258","citationCount":"16","resultStr":"{\"title\":\"Transfusion-Associated Infections with Cytomegalovirus and Other Human Herpesviruses.\",\"authors\":\"Kühn\",\"doi\":\"10.1159/000025258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Of all human herpesviruses, human cytomegalovirus (HCMV) is the most significant cause of transfusion-associated (TA) morbidity and mortality. The problem of TA HCMV infection differs from that of other transfusion-transmitted infections in that only certain groups of patients require HCMV-free blood or blood components, i.e. seronegative pregnant women, premature infants of low birth weight who are born to seronegative mothers, seronegative recipients of allogeneic bone marrow transplants from seronegative donors, seronegative AIDS patients, and seronegative immunosuppressed patients in general. HCMV is strictly cell-associated, and transmission appears to be due to reactivation of latent virus in white blood cells. TA HCMV infec-tion in risk groups can be minimized by selection of HCMV-seronegative donors. Since transmission of HCMV from seropositive donors by blood components containing fewer than 10 7 leukocytes per unit is unlikely, leukodepletion of transfusion products by filtration is an effective alternative to the use of seronegative blood products. Other human herpesviruses causing TA infections are Epstein-Barr virus (EBV) and the human herpesviruses 6 and 7 (HHV-6, HHV-7), whereas transmissions of herpes simplex viruses (HSV-1, HSV-2) and varicella-zoster virus (VZV) by blood transfusion - if occurring at all - are extremely rare events. Frequency and clinical significance of TA infections with the human herpesvirus 8 (HHV-8) have not yet been fully elucidated. Despite the low seroprevalence of HHV-8 in Germany, its oncogenic potential merits attention, and strategies to prevent transmission and spread of HHV-8 by blood and blood products should be discussed. Copyright 2000 S. Karger GmbH, Freiburg</p>\",\"PeriodicalId\":13632,\"journal\":{\"name\":\"Infusionstherapie und Transfusionsmedizin\",\"volume\":\"27 3\",\"pages\":\"138-143\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000025258\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infusionstherapie und Transfusionsmedizin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000025258\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infusionstherapie und Transfusionsmedizin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000025258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16
摘要
在所有人类疱疹病毒中,人类巨细胞病毒(HCMV)是导致输血相关(TA)发病率和死亡率的最重要原因。TA HCMV感染的问题与其他输血传播感染的问题不同,因为只有某些患者群体需要无HCMV的血液或血液成分,即血清阴性的孕妇、血清阴性母亲所生的低出生体重早产儿、血清阴性的异体骨髓移植供者、血清阴性的艾滋病患者和一般的血清阴性免疫抑制患者。HCMV与细胞密切相关,传播似乎是由于白细胞中潜伏病毒的再激活。高危人群的HCMV感染可以通过选择HCMV血清阴性的供者来最小化。由于HCMV不太可能通过每单位含有少于10.7个白细胞的血液成分从血清阳性献血者处传播,因此通过过滤使输血产品的白细胞减少是使用血清阴性血液制品的有效替代方法。其他引起TA感染的人类疱疹病毒是eb病毒(EBV)和人类疱疹病毒6和7 (HHV-6, HHV-7),而单纯疱疹病毒(HSV-1, HSV-2)和水痘带状疱疹病毒(VZV)通过输血传播——如果发生的话——是极其罕见的事件。TA感染人类疱疹病毒8 (HHV-8)的频率和临床意义尚未完全阐明。尽管HHV-8在德国的血清阳性率较低,但其致癌潜力值得关注,应讨论预防HHV-8通过血液和血液制品传播和扩散的策略。版权所有2000 S. Karger GmbH, Freiburg
Transfusion-Associated Infections with Cytomegalovirus and Other Human Herpesviruses.
Of all human herpesviruses, human cytomegalovirus (HCMV) is the most significant cause of transfusion-associated (TA) morbidity and mortality. The problem of TA HCMV infection differs from that of other transfusion-transmitted infections in that only certain groups of patients require HCMV-free blood or blood components, i.e. seronegative pregnant women, premature infants of low birth weight who are born to seronegative mothers, seronegative recipients of allogeneic bone marrow transplants from seronegative donors, seronegative AIDS patients, and seronegative immunosuppressed patients in general. HCMV is strictly cell-associated, and transmission appears to be due to reactivation of latent virus in white blood cells. TA HCMV infec-tion in risk groups can be minimized by selection of HCMV-seronegative donors. Since transmission of HCMV from seropositive donors by blood components containing fewer than 10 7 leukocytes per unit is unlikely, leukodepletion of transfusion products by filtration is an effective alternative to the use of seronegative blood products. Other human herpesviruses causing TA infections are Epstein-Barr virus (EBV) and the human herpesviruses 6 and 7 (HHV-6, HHV-7), whereas transmissions of herpes simplex viruses (HSV-1, HSV-2) and varicella-zoster virus (VZV) by blood transfusion - if occurring at all - are extremely rare events. Frequency and clinical significance of TA infections with the human herpesvirus 8 (HHV-8) have not yet been fully elucidated. Despite the low seroprevalence of HHV-8 in Germany, its oncogenic potential merits attention, and strategies to prevent transmission and spread of HHV-8 by blood and blood products should be discussed. Copyright 2000 S. Karger GmbH, Freiburg